About Jeongseuk Kang
Form D filings for Amaryllis Therapeutics in 2024 list Jeongseuk Kang as chief executive officer and director.
Jeongseuk Kang first appears on SEC filings in 2024.
Experience
This experience comes from SEC filings. The years are when the filings name Jeongseuk Kang in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Jeongseuk Kang works with at each company, as listed on that company's latest Form D.
Amaryllis Therapeutics, Inc. · Form D, Sep 18, 2024
EK
Emmanouil Karagiannis
Director